Primary Care
Obesity
More in Obesity
Plus: oral semaglutide outcomes and incident hypertension in teens on GLP-1 drugs
Participants also had improved cardiometabolic measures with Epitomee device
Health news and commentary gathered by 51˶ staff
Nearly all participants in SURMOUNT-1 avoided diabetes with the GLP-1/GIP receptor agonist
Diagnoses were also delayed the longer sugar was restricted
Messages about unethical industry practices came with less perceived weight stigma
Meta-analysis suggests 24-hour clear liquid diet works to avoid aspiration, even with GLP-1s
Randomized trial achieves a substantial impact with personalized texting, goal-based feedback
Remission of coexisting conditions was also maintained, long-term data show
Patients taking the GLP-1 drug also had greater improvement in physical function
New guidance replaces earlier rec of a 1-week and 1-day hold of injectable and oral GLP-1 agents
However, 24 weeks of the GLP-1 had no impact on eGFR
Researchers observed dose-response relationship for increasing BMI and long COVID risk
